Stockscreener 앱 받기
1.48
3.27%
-0.05
시간 외 거래:
1.46
-0.02
-1.35%
Citius Oncology Inc 주식(CTOR)의 최신 뉴스
What analysts say about Citius Oncology Inc. stockFree Wealth Management Insights - jammulinksnews.com
Is Citius Oncology Inc. a good long term investmentExponential wealth increase - Autocar Professional
What drives Citius Oncology Inc. stock pricePowerful profit generation - Autocar Professional
Citius Oncology Announces Closing of $9.0 Million Public Offering - Eastern Progress
Citius Oncology shares rise 1.31% after-hours after closing a $9.0 million public offering. - AInvest
Should I buy Citius Oncology Inc. stock before earningsShort Term High Return Strategy - Newser
Citius Oncology Completes $9M Public Offering - TipRanks
Citius Oncology Inc. Stock Analysis and ForecastDynamic profit expansion - jammulinksnews.com
Citius Oncology launches $15M equity and warrant offering; shares down - MSN
Citius Oncology closes $9 million public offering to support LYMPHIR - Investing.com Australia
Citius Oncology closes $9 million public offering to support LYMPHIR By Investing.com - Investing.com South Africa
Citius Oncology Raises $9M in Public Offering for LYMPHIR Commercialization - AInvest
Citius Oncology Announces Closing Of $9.0 Million Public Offering - Barchart.com
Citius Oncology Announces Pricing Of $9M "Reasonable Best-Efforts" Public Offering Of 6,818,182 Shares Of Common Stock And Warrants To Purchase Shares Of Common Stock At A Public Offering Price Of $1.32 Per Share - 富途牛牛
Citius Pharmaceuticals shares fall 1.34% after-hours following Citius Oncology's public offering. - AInvest
Citius Oncology’s Chances: Time to Invest? - StocksToTrade
Citius Oncology Announces Pricing of $9.0 Million Public Offering - PR Newswire
Citius Oncology Soars 35.06% on Distribution Deal - AInvest
Citius Oncology Soars 12.34% on Expanded Lymphir Distribution - AInvest
Citius Oncology stock rises after expanding LYMPHIR distribution network - Investing.com
What makes Citius Oncology Inc. stock price move sharplySecure Your Capital Strategy - Newser
Why Citius Oncology Inc. stock attracts strong analyst attentionEarly Breakout Tracker - Newser
Cencora (COR) Partners With Citius Oncology For Immunotherapy Distribution Expansion - simplywall.st
Citius Oncology Shares Climb Following Expansion of LYMPHIR Distribution Network - MSN
Citius Oncology (CTOR): Is LYMPHIR's Launch Priced for Success? - AInvest
Citius Oncology: Is A Lymphir Launch Coming Too Late? - Seeking Alpha
Citius Pharmaceuticals (CTXR) Surges on New Distribution Deal - GuruFocus
Citius Oncology stock rises after expanding LYMPHIR distribution network By Investing.com - Investing.com South Africa
How Citius Oncology Inc. stock performs during market volatilityLow Risk Entry Points - Newser
Citius Oncology Expands Lymphir Distribution With Cencora - MarketScreener
Cencora distribution deal boosts Citius shares - MSN
Citius Oncology expands distribution network for LYMPHIR with Cencora - Investing.com Australia
Citius Oncology expands distribution network for LYMPHIR with Cencora By Investing.com - Investing.com India
Citius stock gains on Cencora distribution deal (CTXR:NASDAQ) - Seeking Alpha
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora - Finansavisen
Citius Oncology shares rise 4.64% after-hours despite plans for stock offering. - AInvest
CTOR Crashes 34%—Is This the Breaking Point for Citius Oncology? - AInvest
Citius Oncology Plans Stock Offering; Shares Down - MarketScreener
Citius Oncology seeks $15M to fund LYMPHIR launch amid going-concern risk | TENKU SEC FilingForm S-1 - Stock Titan
Anchoring Your Portfolio: Is CTOR Stock a Safe Harbor? - investchronicle.com
Citius Pharmaceuticals regains Nasdaq compliance - MSN
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention - PentictonNow
Citius Pharmaceuticals regains Nasdaq compliance after 10-day streak - Investing.com
Citius Pharma Dodges Delisting: Stock Maintains $1+ Price for 10 Straight Days, Secures Nasdaq Future - Stock Titan
1.97%
0.68%
자본화:
|
볼륨(24시간):